Friday 29 September 2023
| 12:15 – 13:15 | Rotterdam Hall 1 | |
|
A Call to Action for Long-Term Disease Control in Autoinflammatory Diseases: Understanding the Role of Biologics
Organized by Medscape Education Global | Supported by independent funding from Novartis |
||
| 12:15 - 12:17 |
Welcome and Introductions Jasmin B. Kuemmerle-Deschner (DE) |
|
| 12:17 - 12:20 |
Patient interview - Uncovering the Journey: A Personal Account of Biologic Therapy From a Patient's Perspective |
|
| 12:20 - 12:30 |
The Domino Effect: Understanding the Long-Term Impact of Chronic Inflammation in Paul van Daele (NL) |
|
| 12:30 - 12:45 |
The Transformative Power of Biologics in Chronic Disease Management: A Before and After Perspective Fabrizio de Benedetti (IT) |
|
| 12:45 - 13:00 |
Panel Discussion - How Will We Use Biologics in the Future: A Critical Appraisal of the Evidence Which Informs Our Decisions Jasmin B. Kuemmerle-Deschner (DE), Fabrizio de Benedetti (IT) & Paul van Daele (NL) |
|
| 13:00 - 13:10 |
Q&A Session Jasmin B. Kuemmerle-Deschner (DE), Fabrizio de Benedetti (IT) & Paul van Daele (NL) |
|
| 13:10 - 13 :15 |
Conclusion Jasmin B. Kuemmerle-Deschner (DE) |
|
| 15:15 – 16:15 | Rotterdam Hall 1 | |
|
A turning point in JIA treatment for the appropriate patient: Exploring tofacitinib’s role
Organized by Pfizer |
||
| 15:15 - 15:20 |
Welcome and faculty introductions Alberto Martini (IT) |
|
| 15:20 - 15:30 |
The current JIA treatment paradigm and unmet needs Ivan Foeldvari (DE) |
|
| 15:30 - 15:40 |
Tofacitinib as a treatment option for patients with pJIA Joost Swart (NL) |
|
| 15:40 - 15:47 |
Patient preference is key to both patients and HCPs prescribing tofacitinib Joost Swart (NL) |
|
| 15:47 - 15:55 |
The role of transitional care in JIA patients Ivan Foeldvari (DE) |
|
| 15:55 - 16:10 |
Faculty Q&A and discussion All |
|
| 16:10 - 16:15 |
Summary and close Alberto Martini (IT) |
|
Saturday 30 September 2023
| 12:15 – 13:15 | Rotterdam Hall 1 | |
|
How I treat Still’s disease in 2023: A case-based discussion
Organized by Sobi |
||
|
Overview of Still’s disease: Pathogenesis, classification and diagnosis Sebastiaan Vastert (NL) |
||
|
SJIA: From diagnosis to remission(?) and everything else in between Paul Brogan (UK) |
||
|
Life-threatening complications in SJIA Alexei Grom (US) |
||
|
Q&A All |
||
| 15:15 – 15:45 | Rotterdam Hall 1 | |
|
Interactive Meet the Expert Session - A practical approach to sJIA management: The timely use of IL-1 inhibitors
Organized by Novartis |
||
|
Speakers: Sebastian Vastert (NL) & Gerd Horneff (DE) |
||
| 15:15 – 15:20 |
Welcome and introduction to the importance of timely initiation of biologics in sJIA Sebastiaan Vastert (NL) & Gerd Horneff (DE) |
|
|
15:20 – 15:35 |
Practical insights into the timely initiation of canakinumab in sJIA Gerd Horneff (DE) |
|
|
15:35 – 15:45 |
Q&A session / panel discussion and close of meeting Sebastiaan Vastert (NL) & Gerd Horneff (DE) |
|
| 15:15 – 15:45 | Rotterdam Hall 2 | |
|
Interactive Meet the Expert Session - Discussing challenging cases in childhood-onset SLE
Organized by GSK |
||
|
Speakers: Alexandre Belot (FR) & Sylvia Kamphuis (NL) Moderation: Roger Levy, GSK |
||
| 15:15 - 15:20 |
Welcome and faculty introductions |
|
| 15:20 - 15:33 |
Clinical case interactive discussion: A young child with monogenetic SLE |
|
| 15:33 - 15:45 |
Clinical case interactive discussion: A 16 year old girl with lupus nephritis and CNS involvement |
|